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ABSTRACT: Background: Lewy body dementia, com-
prising both dementia with Lewy bodies and Parkinson’s
disease dementia, is challenging to manage because of
a complex symptom profile and lack of clear evidence-
based management guidelines.
Objectives: We assessed the feasibility of undertaking a
cluster randomized study of the introduction of an
evidence-based management toolkit for Lewy body
dementia, assessing the outcomes for patients and
carers as secondary measures.
Methods: We randomized 23 memory/dementia, move-
ment disorder, or nonspecialist secondary care services
to the management toolkit or usual care. People with
dementia with Lewy bodies or Parkinson’s disease
dementia underwent assessments of cognition, motor
and neuropsychiatric symptoms, and global outcome at
baseline and 3 and 6 months. Healthcare, personal and
social care costs, and carer-related outcomes of carer
stress, depression, and anxiety were also examined.
Results: A total of 131 participants were recruited (target
120), for whom 6-month data were available on
108 (83%). There was a benefit of being in the interven-
tion arm for carers (reduced Zarit Burden Scale
[P < 0.01], reduced depressive symptoms [P < 0.05]),
who also reported less marked patient deterioration on
the global outcome measure (P < 0.05). There were no
significant differences in other outcomes or in costs
between groups.
Conclusions: The introduction of an evidence-based
management toolkit for Lewy body dementia was feasi-
ble and associated with some benefits, especially for
carers. © 2020 The Authors. Movement Disorders publi-
shed by Wiley Periodicals LLC. on behalf of International
Parkinson and Movement Disorder Society.
Key Words: Lewy body dementia; clinical trial; manage-
ment; dementia with Lewy bodies; Parkinson’s disease
dementia
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Lewy body dementia, comprising both dementia with
Lewy bodies (DLB) and Parkinson’s disease dementia
(PDD), is the second most common degenerative
dementia with limited treatment options and a poor
outcome, including increased mortality, compared with
other dementias.1–4 Recent reviews of pharmacological
and nonpharmacological treatments of DLB and PDD
have highlighted the relative paucity of the evidence
base underpinning current clinical management.5–9
However, these reviews have shown that good evidence
does exist for cholinesterase inhibitors, some limited
evidence for memantine, and there is emerging evidence
for strategies aimed at other key aspects of the disease,
including the management of autonomic symptoms,
parkinsonism, sleep disturbance, and psychosis, espe-
cially visual hallucinations.9,10
The management of Lewy body dementia is challeng-
ing, as patients present with a complex symptom pro-
file, which can vary over time, and treatments for
one symptom (eg, dopaminergic drugs for parkinson-
ism) can exacerbate another (eg, psychosis).1,9 There
are no comprehensive management guidelines in clinical
practice, and internationally regarded organizations
such as the National Institute for Health and Care
Excellence have made only limited recommendations
about some aspects of DLB and PDD, for example,
regarding the use of cholinesterase inhibitors.11,12 Qual-
ity of life is impaired in people with Lewy body demen-
tia and their carers, with studies showing that both in
patients and carers it is even lower than in other
dementias,13,14 and Lewy body dementia is associated
with increased carer stress.15,16 Costs of care may also
be higher in Lewy body dementia than Alzheimer’s
disease.17,18
As part of the National Institute for Health Research–
funded “Improving the Diagnosis and Management of
Neurodegenerative Dementia of Lewy Body Type”
(DIAMOND-Lewy) Programme, we undertook detailed
literature reviews5,7,9 and used this information within
an expert Delphi consensus process to produce a man-
agement toolkit.9 The expert Delphi panel consisted of
26 people from the fields of psychology, geriatrics, psy-
chiatry, neurology, primary care, nursing, and physio-
therapy. The toolkit is aimed at healthcare professionals
involved in the management of people with DLB and/or
PDD. It was developed in close consultation through a
series of meetings with a group of people affected by the
disease and carers, and we engaged with intended users,
that is, healthcare professionals, through extensive
piloting and a review of the toolkit in a service where we
had previously developed an assessment toolkit for the
diagnosis of DLB and PDD.19 The management toolkit
covers both disorders, includes pharmacological and
nonpharmacological recommendations, and is structured
around the key symptom domains of cognition, motor
function, neuropsychiatric features, sleep disturbances,
and autonomic features. The toolkit (which is available
at https://research.ncl.ac.uk/diamondlewy/) consists of
the following 3 parts that can be viewed electronically or
printed and used as a hard copy: (1) a summary sheet,
(2) 5 more detailed sheets covering the aforementioned
symptom domains, and (3) a detailed reference guideline
containing full details of the source of the
recommendations.
We undertook this pilot cluster-randomized con-
trolled trial to see if the introduction of the toolkit to
routine clinical services and the recruitment of DLB and
PPD subjects from within such services was feasible and
as a secondary outcome to collect data on outcome
measures for patients and carers, including whether
costs increased for those allocated to the management
toolkit.
Methods
Trial Design
We performed a pragmatic cluster randomized con-
trolled trial for 26 weeks of 23 clinical services that
assessed people with DLB or PDD, with 1:1 allocation
to either receive the management toolkit or continue
with usual care. This was a pilot study, and the sample
size for subject recruitment was set at 120 (30 DLB and
30 PDD in each arm) on the basis of existing guidance
on sample sizes for pilot studies20 with the aim of
including a range of representative National Health Ser-
vice (NHS) services in which patients with LBD are
seen and to obtain pilot data on patient outcomes to
inform power calculations for a future definitive study.
In the United Kingdom, people with DLB and PDD can
be seen in secondary care services of 3 main types:
memory clinics, movement disorder clinics, and general
secondary care clinics/services for older people. As we
wanted services in this study to be representative of
where DLB and PDD is managed in secondary care, we
included all 3 service types.
At the time of the study, the toolkit was not available
online and was distributed only to those services ran-
domized to receive it. Memory clinics (n = 5), move-
ment disorder clinics (n = 7), and nonspecialist
secondary care clinics/services for older people (n = 11)
from the northeast of England and East Anglia partici-
pated in the study. The trial was supported by the New-
castle Clinical Trials Unit who undertook the
randomization via a statistician blinded to other aspects
of the study. One service was subsequently unable to
recruit any patients and withdrew part way through the
study.
All services received a previously developed assess-
ment toolkit to help diagnose DLB and PDD,19,21 and
for services randomized to the intervention arm, the
management toolkit was introduced during an in-
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person site initiation visit undertaken by the research
team. This comprised standardized presentations and
handouts followed by a question-and-answer session.
All healthcare staff within services allocated to receive
the toolkit were provided with the toolkit and support
in how to use it. Follow-up support and further infor-
mation sessions were available, and the study team
maintained regular contact with all services during the
course of the recruitment and follow-up period.
Assessment and management toolkits were provided
as paper copies with laminated copies of the overview
and symptom summary sheets for the management
toolkit. Some sites requested electronic (.pdf) versions,
and when requested they were supplied.
People with Lewy body dementia and their carers were
recruited during a 21-month period from services ran-
domized to either receive the management toolkit or
continue with usual care. Inclusion criteria for partici-
pants were (1) aged 60 or older and received a diagnosis
of DLB22 or PDD23; (2) considered by the treating clini-
cal team to have at least 1 active clinical problem; and
(3) informed consent could be obtained from the patient
or, for those lacking capacity, from a consultee. A carer/
informant was recruited as an informant wherever possi-
ble to complete scales requiring an informant (all but
2 patients). As we wanted an inclusive and representative
sample, we did not set inclusion criteria based on sever-
ity of dementia or cut-offs on any assessment scale.
Exclusion criteria were (1) patients with a severe or ter-
minal illness and reduced life expectancy that com-
promised their ability to take part and (2) insufficient
English to allow completion of the study measures. As
this was a pilot study, assessing feasibility of recruiting
services and subjects and the utility of our chosen out-
comes, there was no prespecified primary outcome. The
study was approved by the UK National Health Service
Health Research Authority national research ethics com-
mittee (16/WM/0025) and was registered (ISRCTN
11083027).
Trial Assessments
Participants and carers were assessed at baseline and
3 and 6 months. The primary time point for outcome
assessments was at 6 months. All assessments were
undertaken by members of the National Institute for
Health Clinical Research Network, who were indepen-
dent of the study team and unaware of the service allo-
cation (management toolkit or standard care).
Patient-related assessments were of cognition (Mini-
Mental State Examination24 and Montreal Cognitive
Assessment),25 motor symptoms (Unified Parkinson’s Dis-
ease Rating Scale, Part III),26 neuropsychiatric features
(Geriatric Depression Scale,27 Neuropsychiatric Inven-
tory28), quality of life (Dementia Quality of Life Mea-
sure29 and EQ-5D-5L30), and activities of daily living
(Bristol Activities of Daily Living Scale)31 and the Clinical
Global Impression of Change (CGIC) on a 7-point scale
(ranging from 1 = very much worse to 7 = very much bet-
ter, with 4 = no change) as rated by an independent rater
and, as a separate outcome measure, the carer. Carer-
related assessments were of stress (Zarit Burden Scale32)
and mood (Hospital Anxiety and Depression Scale).33
Statistical Analysis
Baseline characteristics between groups were com-
pared using t or Mann-Whitney U tests or, for categori-
cal variables, χ2 tests. Because of the non-normal
distribution of the variables, bootstrapped median
regression analysis was used to determine differences
between groups at 6-month follow-up with adjustments
for baseline values and cluster. CGIC was assessed
using the Wilcoxon Mann-Whitney test and χ2 test. All
of the analyses except the Mann-Whitney U test were
conducted in Stata 16.1 (StataCorp, College Station,
TX). The Mann-Whitney U test was done using SPSS
version 24 (IBM Corp., Armonk, NY).
Health Economic Analysis
Health economic data on the use of health and social
care resources were captured by using a bespoke service
use questionnaire that was developed based on ques-
tions included in the Client Service Receipt Inventory34
and administered to carers at baseline and 3 and
6 months. The participants were asked about their use
of a broad range of services including in-patient ser-
vices, out-patient services, day activity services, and
community care services during the preceding
3 months. Costs were determined for the perspective of
the UK NHS and Personal and Social Services, which
include costs of medications35 and health and social
service use.36,37 Costs falling on other sectors (eg, other
local authority services) were not included. Costs asso-
ciated with the delivery of the toolkit to intervention-
arm participants were included, such as the production
of the management toolkits and training staff to use
them. All costs are reported in pounds sterling (£) for
the financial year 2017/2018. As the study follow-up
was <12 months, no discounting was performed.
Results
A total of 131 participants consented to take part in
the study (see Fig. 1 for Consolidated Standards of
Reporting Trials diagram). Of the carers, 87 were
spouses/partners, 20 were children/children in law,
4 were siblings, 4 were other family members, 6 were
friends, and 5 were paid carers.
A total of 127 participants underwent a baseline
assessment, and 6-month data were available for
109 (83% of all participants who consented, 86% of
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those who completed baseline, respectively). Of the par-
ticipants, 18 were lost to follow-up, 7 of whom died
(4 in the intervention arm; 3 in the control arm). Those
lost to follow-up were similar in demographic charac-
teristics to those remaining in the study except for age:
those lost to follow-up were significantly older (median
age of 83 compared with median age of 77; U
value = 547; P = 0.003).
We exceeded the recruitment target, aiming to recruit
120 patients and actually recruiting 131. Patient characteris-
tics at baseline are shown in Table 1. Participants random-
ized to receive the intervention did not differ significantly
from those randomized to the usual care group on any of
the baseline measures except for carer-reported Dementia
Quality of Life Measure and carer anxiety symptoms on
the Hospital Anxiety and Depression Scale. Changes in sec-
ondary outcomes at study end (6 months) are shown in
Table 2. Controlling for baseline measures and interclass
clustering coefficient, there were significant improvements in
carer-related outcomes of carer burden (Zarit Burden Scale;
difference, −6.9; 95% confidence interval, −12.4 to −1.4;
P = 0.011) and depressive symptoms (Hospital Anxiety and
Depression Scale; difference, −1.2; 95% confidence interval,
–2.8 to −0.1; P = 0.043). There were no significant differ-
ences in other scales.
Outcomes using the clinical global impression of change
are shown in Figure 2. There was a trend for fewer sub-
jects in the toolkit arm to be rated as worse or very much
worse. This was not significant for the independent rater
CGIC (Mann-Whitney U, 1195; P = 0.11). However, sig-
nificantly fewer participants in the toolkit arm were rated
as worse or very much worse for the carer-rated CGIC
(Mann-Whitney U, 1032; P = 0.03). To further illustrate
this, the proportion of subjects who showed marked
FIG 1. Study Consolidated Standards of Reporting Trials diagram. CRF, case report form.
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deterioration (much or very much worse) was lower in the
toolkit arm compared with usual care (17% vs. 33% for
independently rated [χ2, 3.79; P = 0.051]; 19% vs. 42%
for carer rated [χ2, 6.56; P = 0.01]).
Using results from this study to inform a power cal-
culation for a future study (80% power, α = 0.05) gives
a required sample size of 328 for clinician-rated global
outcome (17.2% much/very much worse in the
intervention group compared with 33.3% in the control
group). Assuming 80% completion rates, then a recruit-
ment sample of 410 would be required.
Staff Who Used the Toolkit
We did not collect detailed demographic information
on which staff members used the toolkit given the focus
TABLE 1. Baseline characteristics of the randomized participants
Control, n = 52 Intervention, n = 75 P Value*
Number of sites 11 12
Service type (memory clinic/general/PD clinic) 2/6/3 3/5/4
Age, y, mean (SD) 77.0 (7.59) 79.3 (6.97) 0.086
Diagnosis, DLB:PDD, n (%) 31:21 (60:40) 46:29 (61:39) 0.846
Sex, female:male, n (%) 10:42 (19:81) 17:58 (23:77) 0.642
DEMQOL
Mean (SD) 0.76 (0.13) 0.78 (0.12)
Median (interquartile range) 0.78 (0.70–0.82) 0.80 (0.70–0.88) 0.215
Carer DEMQOL-proxy
Mean (SD) 0.70 (0.14) 0.76 (0.12)
Median (interquartile range) 0.67 (0.55–0.82) 0.79 (0.67–0.85) 0.026
NPI
Mean (SD) 25.0 (17.5) 20.0 (18.0)
Median (interquartile range) 22.0 (12.0–31.0) 15.0 (9.0–24.0) 0.038
UPDRS
Mean (SD) 43.7 (19.1) 38.2 (18.6)
Median (interquartile range) 41.0 (28.0–55.0) 35.5 (26.0–51.0) 0.137
Cornell Depression Scale
Mean (SD) 9.31 (6.10) 7.41 (4.85)
Median (interquartile range) 9.0 (4.0–13.0) 7.0 (4.0–11.0) 0.104
Geriatric Depression Scale
Mean (SD) 5.7 (3.5) 5.6 (3.3)
Median (interquartile range) 5.0 (3.0–7.0) 5.0 (3.0–7.0) 0.952
MMSE
Mean (SD) 20.8 (6.1) 21.4 (6.1)
Median (interquartile range) 22.0 (17.0–25.0) 22.0 (19.0–26.0) 0.503
MoCA
Mean (SD) 15.1 (4.9) 15.6 (6.0)
Median (interquartile range) 15.5 (12.0–19.0) 16.0 (12.0–19.0) 0.690
EQ-5D-5L
Mean (SD) 0.67 (0.27) 0.67 (0.21)
Median (interquartile range) 0.74 (0.55–0.85) 0.73 (0.57–0.80) 0.516
EQ-5D-5L (proxy)
Mean (SD) 0.55 (0.27) 0.56 (0.27)
Median (interquartile range) 0.62 (0.37–0.73) 0.62 (0.40–0.77) 0.929
HADS anxiety
Mean (SD) 6.7 (4.2) 5.2 (4.1)
Median (interquartile range) 6.0 (3.0–9.0) 4.0 (2.0–8.0) 0.037
HADS depression
Mean (SD) 4.6 (3.8) 4.2 (3.5)
Median (interquartile range) 3.0 (1.0–7.0) 3.5 (1.0–7.0) 0.610
Zarit Burden Scale
Mean (SD) 27.5 (15.6) 22.6 (15.3)
Median (interquartile range) 26.0 (14.5–38.5) 18.0 (10.0–33.0) 0.070
Carer EQ-5D-5L
Mean (SD) 0.80 (0.20) 0.81 (0.19)
Median (interquartile range) 0.84 (0.72–1.0) 0.82 (0.69–1.0) 0.902
*P-value from t test, Mann-Whitney test, or χ2 test.
Abbreviations: SD, standard deviation; DLB, dementia with Lewy bodies; PDD, Parkinson’s disease dementia; DEMQOL, Dementia Quality of Life Measure; NPI,
Neuropsychiatric Inventory; UPDRS, Unified Parkinson’s Disease Rating Scale; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment;
EQ-5D, European Quality of Life 5 Dimensional Scale; HADS, Hospital Anxiety and Depression Scale.
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on adoption of the toolkit at the team/service level,
although we did undertake a survey during the study
asking those who used to toolkit to reply with feed-
back. Replies were obtained from 34 people, 17 (50%)
consultant medical staff, 7 (21%) medical staff below
consultant grade, 8 (24%) nursing staff, and 2 (6%)
allied health professionals.
Healthcare and Social Service Resource Use
As this was a pilot study, the focus of the economic
component was to provide a descriptive analysis of the
costs for participants in each arm (toolkit or usual care)
and these are shown in Table 3. The total delivery cost of
the management toolkit was divided by the number of
participants in the intervention arm (n = 75) to estimate a
mean delivery cost per participant (£76.32) receiving the
intervention. This was added for each participant in the
toolkit arm, with no costs added for those receiving usual
care (ie, the control arm). Mean costs associated with
healthcare and social service use reduced in the toolkit
arm between baseline and 6-month follow-up, whereas in
the usual care group costs increased. There is a substantial
amount of imprecision around the service use cost data,
and there was no evidence of a difference. Mean medica-
tion costs increased slightly in both arms. There was slight
evidence that on average the toolkit arm cost increased
more from baseline than the usual-care arm (toolkit base-
line [mean  standard deviation], £223  £204, and
6 months, £294  £286; usual care baseline, £214  239,
and 6 months, £229  206; group difference, P = 0.098).
Discussion
Our pilot cluster-randomized trial investigated the
introduction of an evidence-based management toolkit
for Lewy body dementia compared with usual care in
representative clinical services in England. We showed
that such a study was feasible. We were able to recruit
a sufficient number of memory/dementia, movement
disorder, and nonspecialist services for older people to
participate and to recruit participants in all but 1 of
these. Furthermore, participant recruitment exceeded
our original intended goal (final number recruited 137;
target of 120). We obtained 24-week data on 83% of
TABLE 2. Change from baseline to 6 months: results of bootstrapped (replications 1000) median regression, adjusting for
baseline values and cluster
Assessment timepoint Standard Care Intervention Difference (95% CI) P Value
Number of sites 11 12
DEMQOL, n = 86 Baseline
6 months
0.78 (0.70, 0.83)
0.79 (0.7, 0.86)
0.80 (0.70, 0.88)
0.84 (0.77, 0.88)
0.03 (−0.02 to 0.07) 0.268
Carer DEMQOL-proxy, n = 103 Baseline
6 months
0.70 (0.62, 0.82)
0.78 (0.56, 0.82)
0.79 (0.67, 0.85)
0.82 (0.70, 0.87)
0.03 (−0.02 to 0.09) 0.185
NPI, n = 105 Baseline
6 months
22.5 (12.0, 30.0)
20.0 (11.0, 33.0)
14.0 (9.0, 26.0)
11.0 (5.0, 24.0)
−1.8 (−6.2 to 2.6) 0.408
UPDRS, n = 94 Baseline
6 months
40.0 (30.0, 55.0)
43.0 (34.0, 60.0)
35.0 (25.0, 51.0)
37.0 (25.0, 52.5)
−2.3 (−7.9 to 3.4) 0.428
Cornell Depression Score, n = 105 Baseline
6 months
9.0 (4.0, 12.5)
9.0 (4.0, 14.0)
7.0 (4.0, 11.0)
6.0 (3.0, 10.0)
−1.5 (−3.9 to 0.81) 0.198
Geriatric Depression Scale, n = 92 Baseline
6 months
5.0 (3.0, 7.0)
6.0 (3.0, 8.0)
6.0 (3.0, 7.0)
5.0 (4.0, 8.0)
−0.5 (−1.9 to 0.9) 0.469
MMSE, n = 98 Baseline
6 months
22.0 (12.5, 25.5)
22.0 (17.0, 26.0)
22.5 (19.0, 27.0)
22.0 (17.0, 25.0)
0.5 (−1.4 to 2.5) 0.607
MoCA, n = 93 Baseline
6 months
15.5 (12.0, 19.0)
16.0 (12.0, 18.5)
16.0 (13.0, 20.0)
16.0 (12.0, 19.0)
0.5 (−2.1 to 3.0) 0.722
EQ-5D-5L, n = 89 Baseline
6 months
0.78 (0.55, 0.88)
0.67 (0.56, 0.84)
0.71 (0.55, 0.78)
0.68 (0.57, 0.78)
0.05 (−0.04 to 0.15) 0.242
Proxy EQ-5D-5L, n = 101 Baseline
6 months
0.65 (0.45, 0.73)
0.57 (0.43, 0.71)
0.63 (0.43, 0.79)
0.67 (0.39, 0.80)
0.06 (−0.05 to 0.17) 0.246
HADS anxiety, n = 101 Baseline
6 months
6.5 (3.0, 9.0)
6.0 (4.0, 9.0)
4.0 (2.0, 8.0)
5.0 (2.0, 9.0)
0.04 (−2.1 to 2.2) 0.973
HADS depression, n = 101 Baseline
6 months
3.0 (2.0, 7.0)
4.0 (2.0, 6.0)
4.0 (1.0, 7.0)
3.0 (1.0, 6.0)
−1.2 (−2.8 to −0.1) 0.043
Zarit Burden Scale, n = 99 Baseline
6 months
26.0 (14.0, 36.0)
29.5 (16.0, 42.0)
22.0 (13.0, 34.0)
23.5 (10.0, 32.0)
−6.9 (−12.4 to −1.4) 0.011
Carer EQ-5D-5L, n = 102 Baseline
6 months
0.84 (0.71, 1.0)
0.80 (0.74, 0.91)
0.84 (0.70, 1.0)
0.84 (0.77, 1.0)
0.04 (−0.06 to 0.15) 0.419
Significance values indicate median and inter-quartile range. Abbreviations: CI, confidence interval; DEMQOL, Dementia Quality of Life Measure; NPI, Neuropsy-
chiatric Inventory; UPDRS, Unified Parkinson’s Disease Rating Scale; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; EQ-5D,
European Quality of Life 5 Dimensional Scale; HADS, Hospital Anxiety and Depression Scale.
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consented participants. Although there was no evidence
of any difference in many of the assessment scales, this
is unsurprising in view of the pilot nature of the study,
which was not powered to detect such differences.
Nonetheless, there was a trend (P = 0.051) for differ-
ences on the CGIC with less severe or very severe dete-
rioration in the patient group managed within services
allocated to the management toolkit, with this outcome
becoming significant (P = 0.01) when rated by carers.
Global outcome has been shown in previous pharmaco-
logical studies of Lewy body dementia to be 1 of the
most consistent of all outcome measures to show a
treatment effect.5,38 The reasons for this are not clear
but may include the well-recognized marked fluctua-
tions in Lewy body dementia that may make more spe-
cific scales less reliable in detecting change compared
with other dementias such as Alzheimer’s disease or
that the global outcome detects a number of small bene-
fits that sum to make a global difference. This is partic-
ularly likely for our management toolkit, which was
applied in a bespoke individualized way, according to
the symptoms each patient had, which may be better
detected by a global measure. In addition, carers may
be particularly sensitive to the particular symptoms
being managed in their case and also see patients during
a longer time period, which may be why they detected
change better than an independent rater. Our findings
support those from some previous pharmacological
studies, suggesting that global outcome is a sensitive
measure that could be used as a primary outcome in
future studies.
We also found important benefits for carers, with
reduced stress assessed using the Zarit Burden Scale
and reduced depressive symptoms. High levels of bur-
den and stress are well recognized in carers of people
with dementia. This is especially so for carers of those
with Lewy body dementia, likely attributed to the
complexity of caring for those with a complex and fluc-
tuating disorder with cognitive, motor, and neuropsy-
chiatric symptoms.15,16 There have been no studies
investigating ways of reducing stress or burden in those
with Lewy body dementia, and so our findings that the
introduction of the management toolkit may improve
these symptoms is striking. Although the magnitude of
the changes was modest, it could conceivably have been
the case that use of the management toolkit might even
have increased burden and stress. We showed this was
not the case, and further work should seek to investi-
gate whether there are particular components of the
management toolkit that are most associated with alle-
viating carer stress. Lewy body dementia is associated
with a particularly poor outcome in terms of cognitive
and functional declines and increased mortality.3 There
FIG 2. Outcome in terms of rating on the clinical global impression of
change at 6 months on the Clinical Global Impression of Change as
rated by (a) an independent rater (group difference P = 0.11) and (b) the
carer (group difference P = 0.03).
TABLE 3. Total care costs by intervention arm
Intervention Usual care Difference
(intervention - control) p-value*
N** Mean SD N Mean SD
NHS&PSS resources
Baseline 75 £2,153 £4,283 52 £1,373 £1,816 £779 >0.1
6MFU 64 £1,333 £1,393 45 £1,873 £3,825 −£540 >0.1
NHS resources only
Baseline 75 £1,784 £4,057 52 £1,032 £1,293 £752 >0.05
6MFU 64 £831 £584 45 £1,386 £3,658 −£555 >0.05
PSS resources only
Baseline 75 £589 £1,244 52 £555 £1,158 £34 >0.1
6MFU 64 £872 £1,280 45 £716 £1,309 £156 >0.1
* p-value from t-test with equal variances.
Abbreviations: NHS = National Health Service costs; PSS = Personal social care costs.
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was no difference in mortality between those in services
with or without the management toolkit, although this is
unsurprising given most participants had mild or moder-
ate disease and the short duration of the study, leading
to low mortality rates. There was no evidence of a differ-
ential effect of the toolkit for those with DLB or PDD.
The introduction of any evidence-based guideline or
toolkit comes with a risk that costs may increase either
because of the use of more expensive medication,
greater investigations or more referrals to other agen-
cies, or increased levels of care as needs become more
apparent. We found no evidence of increased costs
associated with the use of the management toolkit.
However, the level of imprecision was such that eco-
nomically important differences could exist. There was
a tendency for costs to increase slightly over 6 months
in those allocated to the usual-care arm and decrease in
those in the management toolkit arm, and although
these differences were not statistically significant, they
may have an economic impact. Interestingly, although
costs decreased in the toolkit arm, medication costs
showed a trend to rise that would be consistent with
the many pharmacological recommendations in the
toolkit. Any further evaluation should include cost-
effectiveness as a core component and seek to under-
take a rigorous cost-effectiveness analysis, which was
not possible because of our modest sample size. Because
the costs of Lewy body dementia are higher than other
dementias,17,18 the demonstration of cost savings would
be important to health services.
The strengths of this study include the systematic
introduction of an evidence-based toolkit in a cluster-
randomized design to representative services. We also
aimed to include representative patients with Lewy body
dementia, so inclusion criteria were broad with no limit
set for dementia severity. The severity in terms of cogni-
tive and other features, however, is broadly representa-
tive of those described in other naturalistic cohorts.
Importantly, outcome assessments including the clini-
cian-rated and carer-rated outcomes were undertaken
without knowledge of whether the person with Lewy
body dementia was being managed within a service allo-
cated to the management toolkit or usual care.
We recognize several limitations to the study. This
was a pilot study and therefore underpowered, with
efficacy as a secondary outcome, and although it gener-
ated evidence of differences for carer-related measures,
none would have survived correction for multiple com-
parisons, and only for global outcome was there evi-
dence of a difference for patient related measures.
Sample size, although relatively large for a study of
Lewy body dementia, was still modest to make defini-
tive conclusions about the benefits of the toolkit. Given
that even usual-care sites knew they were participating
in a study of Lewy body dementia, this may have
prompted them to focus more on the management of
this condition than may be usual at times when studies
are not being undertaken. This would tend to reduce
our ability to detect a difference. Although raters of the
outcome measures were blind to subject group alloca-
tion, we cannot be sure that the participants themselves
or carers were fully blinded as to which arm they were
allocated. The management toolkit is evidence based,
but most of the recommendations are available already
from published literature. Therefore, many participants
in the usual-care arm would be receiving treatment rec-
ommended in the toolkit (eg, cholinesterase inhibitors
are National Institute for Health and Care Excellence–
recommended treatments for all people with Lewy body
dementia, unless otherwise contraindicated). As we
introduced the toolkit to whole services, we could not
assess the extent to which the toolkit was used with
individual patients. We did not collect detailed informa-
tion about the users of the management toolkit,
although our survey indicated that the majority (50%)
were experienced (consultant) medical staff and that
around 30% of healthcare professionals who used the
toolkit were nonmedical (largely nursing staff). A quali-
tative process evaluation was conducted alongside the
pilot trial that included participant interviews and site
observations. Although outside scope for this article,
the qualitative findings provided additional insights into
how the toolkit was implemented and used within sites.
The toolkit was a broad intervention consisting of a
number of recommendations, so we cannot directly deter-
mine the “mechanism of action” or “dose” of the toolkit,
and further studies should include measures that could
directly assess this. However, every recommendation was
based either on published evidence or from a Delphi con-
sensus and has been published, and the recommendations
should be useful to those involved in the management
and care of people with DLB and PDD.9 Finally, as this
study was performed in secondary care services within a
single country, we cannot necessarily generalize our find-
ings to other countries or healthcare settings.
In conclusion, we undertook a pilot cluster-randomized
study of an evidence-based toolkit in Lewy body demen-
tia. Our results show that such studies are feasible, with
benefits suggested for measures of global outcome for
patients and carer measures of reduced burden and
depressive symptoms. Importantly, there was no evidence
that the introduction of the management toolkit may
potentially increase costs. Further work should investigate
the impact of wider implementation of the toolkits, either
through a much larger trial (which would need to include
>400 subjects) or through other methods including clini-
cal audit or realist evaluation. Future research should also
investigate other outcomes, including those that may be
more relevant and salient to people with Lewy body
dementia and their carers, and positive outcome measures
(for both people with dementia and carers) such as resil-
ience, coping, and efficacy.39,40
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